

**Faculty of Pharmacy**

**Ain Shams University**

**Pharmacology and Toxicology Department**



**“The potential curative effect of galangin against  
experimentally induced ulcerative colitis”**

A thesis submitted for partial fulfillment of the requirements of the Master's  
Degree in Pharmaceutical Sciences (Pharmacology and Toxicology)

By

**Samar Hosni Gerges Nesr**

B.Sc. Pharmacy (2014), Faculty of Pharmacy, Ain Shams University

Under the supervision of

**Prof. Ebtahal El-Demerdash Zaki**

Professor and Head of Pharmacology and Toxicology Department,  
Faculty of Pharmacy, Ain Shams University

**Dr. Doaa Ahmed Elsherbiny**

Lecturer, Pharmacology and Toxicology Department,  
Faculty of Pharmacy, Ain Shams University

**Dr. Mai Fathy Tolba**

Lecturer, Pharmacology and Toxicology Department,  
Faculty of Pharmacy, Ain Shams University



## **Acknowledgements**

At the beginning, I wish to express my sincere thanks and gratitude to my supervisors; they were exemplary in their roles as researchers, mentors, and teachers.

I wish to express my appreciation and gratitude to **Prof. Ebtehal El-Demerdash**, Professor and Head of Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, for being very generous with her knowledge. She has made this work possible by her continuous guidance, support, and precious advices throughout the whole study including practical work and thesis writing.

I am deeply thankful to **Dr. Doaa Ahmed Elsherbiny**, Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for her continuous help and support in all aspects, and for her tremendous efforts in reviewing the thesis. She never stopped supporting and guiding me throughout the whole study.

Most heartfelt thanks are due to **Dr. Mai Fathy Tolba**, Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for choosing the research point and for being very helpful, supportive, and kind. I am also very grateful for her great efforts in the practical work and in reviewing the thesis.

I would like to thank **Dr. Adel Bakir**, Professor of Pathology, Faculty of Veterinary Medicine, Cairo University, for his sincere help in histopathology, and **Dr. Ahmed Erfan**, Head of Biotechnology Unit, Animal Health Research Institute, for his kind help in real-time PCR.

I would like to thank all my Professors and colleagues at the Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University, for their kind and sincere support throughout my study.

Finally, I would like to thank my family: my father, my mother, and my brother for giving me all the love and wholehearted support to continue. Without their unconditional love and understanding, I could hardly endure the hard times throughout my study.

***Samar Hosni***



# Contents

<b>Subject</b>	<b>Page</b>
List of Abbreviations	I
List of Tables	IV
List of Figures	VI
Abstract	1
Introduction	
1. Inflammatory bowel diseases	2
2. Pathogenesis of inflammatory bowel diseases	5
3. Risk of colorectal cancer	23
4. Experimental models of inflammatory bowel diseases	24
5. Management of inflammatory bowel diseases	25
6. Propolis	30
7. Galangin	30
8. Sulfasalazine	38
Aim of the Work	43
Material and Methods	
(A) Experimental design	45
(B) Material	50
(C) Methods	54
Results	77
Discussion	125
Summary and Conclusion	137
References	142
Arabic Summary	i



## **List of Abbreviations**

<b>Abbreviation</b>	<b>Meaning</b>
<b>5-ASA</b>	5-Aminosalicylic acid
<b>ANOVA</b>	Analysis of variance
<b>Anti-TNF</b>	Anti-tumor necrosis factor
<b>B(a)P</b>	Benzo(a)pyrene
<b>CARD9</b>	Caspase recruitment domain-containing protein 9
<b>CAT</b>	Catalase
<b>CD</b>	Crohn's disease
<b>Con A</b>	Concavalin A
<b>COX</b>	Cyclooxygenase
<b>COX-2</b>	Cyclooxygenase-2
<b>CRC</b>	Colorectal cancer
<b>DAI</b>	Disease activity index
<b>DAMPs</b>	Damage-associated molecular patterns
<b>DCs</b>	Dendritic cells
<b>DSS</b>	Dextran sulfate sodium
<b>DTT</b>	Dithiothreitol
<b>ELISA</b>	Enzyme-linked immunosorbent assay
<b>ERK</b>	Extracellular signal-regulated kinases
<b>GIT</b>	Gastrointestinal tract
<b>GPx</b>	Glutathione peroxidase
<b>GSH</b>	Reduced glutathione
<b>H &amp; E</b>	Hematoxylin and eosin
<b>HMGB1</b>	High mobility group box protein 1
<b>HRP</b>	Horseradish peroxidase
<b>HSV-1</b>	Herpes simplex virus type 1
<b>IBDs/IBD</b>	Inflammatory bowel diseases
<b>IECs</b>	Intestinal epithelial cells
<b>IL-1</b>	Interleukin 1

<b>IL-1<math>\beta</math></b>	Interleukin 1 beta
<b>IL-6</b>	Interleukin 6
<b>IL-8</b>	Interleukin 8
<b>IL-13</b>	Interleukin 13
<b>IL-17</b>	Interleukin 17
<b>IL-23</b>	Interleukin 23
<b>iNOS</b>	Inducible nitric oxide synthase
<b>IRAKs</b>	Interleukin 1 receptor-associated kinases
<b>IV</b>	Intravenous
<b>I<math>\kappa</math>B</b>	Inhibitor kappa B
<b>JNK</b>	c-jun N-terminal kinase
<b>LDH</b>	Lactate dehydrogenase
<b>LH</b>	Lipid hydroperoxides
<b>LOX</b>	Lipoxygenase
<b>LPS</b>	Lipopolysaccharides
<b>MAPKs</b>	Mitogen-activated protein kinases
<b>MBL</b>	Metallo-beta-lactamase
<b>MDA</b>	Malondialdehyde
<b>MDP</b>	Muramyl dipeptide
<b>MIC</b>	Minimum inhibitory concentration
<b>MyD88</b>	Myeloid differentiation primary response protein 88
<b>Na CMC</b>	Sodium carboxymethyl cellulose
<b>NADH</b>	Nicotinamide adenine dinucleotide
<b>NF-<math>\kappa</math>B</b>	Nuclear factor kappa-light-chain-enhancer of activated B cells
<b>NLRs</b>	NOD-like receptors
<b>NOD2</b>	Nucleotide-binding oligomerization domain-containing protein 2
<b>NSAIDs</b>	Non-steroidal anti-inflammatory drugs
<b>OCPs</b>	Oral contraceptives
<b>OD</b>	Optical density
<b>OVA</b>	Ovalbumin
<b>PAMPs</b>	Pathogen-associated molecular patterns

<b>PBS</b>	Phosphate buffered saline
<b>PCR</b>	Polymerase chain reaction
<b>PI3K</b>	Phosphoinositide 3-kinase
<b>PIC</b>	Protease inhibitor cocktail
<b>PRRs</b>	Pattern recognition receptors
<b>RANKL</b>	Receptor activator of nuclear factor kappa B ligand
<b>ROS</b>	Reactive oxygen species
<b>SD</b>	Standard deviation
<b>SOD</b>	Superoxide dismutase
<b>SP</b>	Streptavidin-peroxidase
<b>TBA</b>	Thiobarbituric acid
<b>TBARS</b>	Thiobarbituric acid reactive substances
<b>TBS</b>	Tris buffered saline
<b>TGF-<math>\beta</math></b>	Transforming growth factor beta
<b>TLR4</b>	Toll-like receptor 4
<b>TLRs</b>	Toll-like receptors
<b>TNF-<math>\alpha</math></b>	Tumor necrosis factor alpha
<b>Treg</b>	Regulatory T cells
<b>UC</b>	Ulcerative colitis



## **List of Tables**

Table (1): Drugs, chemicals, kits, antibodies, and equipment used in the study.....	50
Table (2): Primer sequences of the investigated genes.....	53
Table (3): Cycling conditions for SYBR green real-time PCR according to Quantitect SYBR green PCR kit.....	62
Table (4): Daily disease activity index scores of the five experimental groups .....	78
Table (5): The severity of histopathological alterations in the five experimental groups after the dose-selection study.....	84
Table (6): The effect of treatment with different doses of galangin (20, 40, and 80 mg/Kg) on NF- $\kappa$ B protein abundance in DSS-induced mice.....	86
Table (7): The effect of treatment with different doses of galangin (20, 40, and 80 mg/Kg) on iNOS protein abundance in DSS-induced mice.....	90
Table (8): The percentage of body weight change in the five experimental groups at the end of the mechanistic study.....	95
Table (9): The severity of histopathological alterations in the five experimental groups after the mechanistic study.....	100
Table (10): The effect of treatment with galangin, sulfasalazine, and a combination of both on serum LDH activities in DSS-induced mice.....	102
Table (11): The effect of treatment with galangin, sulfasalazine, and a combination of both on relative TLR4 mRNA expression levels in DSS-induced mice.....	105
Table (12): The effect of treatment with galangin, sulfasalazine, and a combination of both on NF- $\kappa$ B p65 nuclear concentrations in DSS-induced mice.....	108

Table (13): The effect of treatment with galangin, sulfasalazine, and a combination of both on tissue IL-6 concentrations in DSS-induced mice..	111
Table (14): The effect of treatment with galangin, sulfasalazine, and a combination of both on tissue TNF- $\alpha$ concentrations in DSS-induced mice.....	114
Table (15): The effect of treatment with galangin, sulfasalazine, and a combination of both on relative HMGB1 mRNA expression levels in DSS-induced mice.....	117
Table (16): The effect of treatment with galangin, sulfasalazine, and a combination of both on tissue GSH concentrations in DSS-induced mice.....	120
Table (17): The effect of treatment with galangin, sulfasalazine, and a combination of both on tissue MDA concentrations in DSS-induced mice.....	123

## **List of Figures**

Figure 1: Factors involved in IBD pathogenesis.....	6
Figure 2: The intestinal epithelial barrier in normal and IBD states.....	15
Figure 3: Signaling through all TLRs finally leads to the activation and nuclear translocation of NF- $\kappa$ B and MAPKs.....	17
Figure 4: The TLR4/NF- $\kappa$ B signaling pathway.....	19
Figure 5: Chemical structure of galangin.....	31
Figure 6: Chemical structure of sulfasalazine.....	39
Figure 7: Experimental design of the dose-selection study.....	46
Figure 8: Experimental design of the mechanistic study.....	48
Figure 9: Standard calibration curve of NF- $\kappa$ B p65.....	67
Figure 10: Standard calibration curve of IL-6.....	70
Figure 11: Standard calibration curve of TNF- $\alpha$ .....	73
Figure 12 (A,B): Disease activity index scores of the five experimental groups.	
12A: Data are represented as median and interquartile range.....	79
12B: Data are represented as median, error bars are omitted for clarity..	79
Figure 13: Disease activity index scores of the five experimental groups on the last day of the dose-selection study.....	80
Figure 14: Histopathological findings in the five experimental groups after the dose-selection study.....	82
Figure 15: The effect of treatment with different doses of galangin (20, 40, and 80 mg/kg) on NF- $\kappa$ B protein abundance .....	87

Figure 16: Immunohistochemical staining images of NF- $\kappa$ B.....	88
Figure 17: The effect of treatment with different doses of galangin (20, 40, and 80 mg/kg) on iNOS protein abundance .....	91
Figure 18: Immunohistochemical staining images of iNOS.....	92
Figure 19: Body weights of mice in the five experimental groups over the mechanistic study period.....	96
Figure 20: Histopathological findings in the five experimental groups after the mechanistic study.....	98
Figure 21: The effect of treatment with galangin, sulfasalazine, and a combination of both on serum LDH activities.....	103
Figure 22: The effect of treatment with galangin, sulfasalazine, and a combination of both on the mRNA expression levels of TLR4.....	106
Figure 23: The effect of treatment with galangin, sulfasalazine, and a combination of both on nuclear concentrations of NF- $\kappa$ B p65.....	109
Figure 24: The effect of treatment with galangin, sulfasalazine, and a combination of both on tissue IL-6 concentrations .....	112
Figure 25: The effect of treatment with galangin, sulfasalazine, and a combination of both on tissue TNF- $\alpha$ concentrations .....	115
Figure 26: The effect of treatment with galangin, sulfasalazine, and a combination of both on the mRNA expression levels of HMGB1.....	118
Figure 27: The effect of treatment with galangin, sulfasalazine, and a combination of both on tissue GSH concentrations.....	121

Figure 28: The effect of treatment with galangin, sulfasalazine, and a combination of both on tissue MDA concentrations .....	124
-------------------------------------------------------------------------------------------------------------------------------	-----